I’ve been so far down the immunogenicity —- > aggregates —-> filtering road I got to the “forgot more than you know” level on these topics lol. The snarky comment gave me the opportunity “to pull it all together” and remind myself of why I filter all this stuff. Not just to reduce the risk of potential harm to health, but to ensure these things keep working by minimizing immunogenicity and the potential of ling term or even lifelong decreased effectiveness of critically important drugs.
One retort I got in the past was “there is no immunogenicity problem with rHGH any more”, which is largely true, and an appealing argument. But that’s not an accident, and doesn’t apply to UGL. It’s the result of 30 years of progress by Pharma / FDA making sure that’s the case with things like increasingly stricter limits on aggregates and preventing their formation, something that’s completely out of control with UGL.
And that applies to all UGL peptides.
You almost couldn’t engineer a worse set of conditions to maximize immunogenicity risk than we have with UGL peptides / protein drugs,